Skip to main content
OABI
NASDAQ Life Sciences

OmniAb Lifts 2026 Revenue and Cash Guidance After Q3 Revenue Nearly Doubles

Tom Rudovsky · Reported by BusinessWire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$5.2
Mkt Cap
$760.392M
52W Low
$1.3
52W High
$5.43
52W Position info
300% above low
Off High info
4.2% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

OABI has more than doubled off its 52-week low of $1.3.

Summary

OmniAb raised full-year 2026 revenue guidance to $35-39 million from $32-36 million and lifted its year-end cash outlook to $53-57 million from $49-53 million, while cutting its 2026 cost outlook to $83-87 million from $84-88 million and cash costs to $50-54 million from $51-55 million. Q3 revenue came in at $4.0 million versus $2.2 million a year earlier, driven by service work on antibody and ion channel programs plus higher xPloration instrument and consumable sales. The quarter still carried a $15.7 million net loss, or $0.12 per share, though that narrowed from $16.5 million a year ago, and the company held $64.2 million in cash, equivalents and short-term investments at September 30. The bigger swing this year came earlier: nine-month revenue reached $31.8 million versus $10.3 million, mostly from milestone revenue, following the August Eli Lilly ion channel collaboration worth up to $370 million in milestones. Management also flagged the broad commercial launch of xPloration in October, targeting a market it pegs at more than $500 million, with xPloration revenue expected at $2-3 million in 2026 and doubling in each of 2027 and 2028. The 8:00 a.m. ET call today is where guidance credibility and the xPloration ramp get tested.

Updated with an SEC 8-K filing · What changed

Updates

  1. · SEC 8-K — OmniAb cut its 2026 cost outlook to $83-87 million from $84-88 million and cash costs to $50-54 million from $51-55 million.

At the time of this announcement, OABI was trading at $5.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $760.4M. The 52-week trading range was $1.30 to $5.43. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

OABI - Latest Insights

OABI
Oct 30, 2026, 7:42 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.00
Real-time Price: $4.78 info
Change: -$0.220 (-4%) info
Market Cap: $716.174M info
OABI
Aug 17, 2026, 6:01 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $3.33
Real-time Price: $4.78 info
Change: +$1.45 (+44%) info
Market Cap: $716.174M info
OABI
Aug 06, 2026, 4:40 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $2.40
Real-time Price: $4.78 info
Change: +$2.38 (+99%) info
Market Cap: $716.174M info
OABI
Aug 06, 2026, 4:11 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.30
Real-time Price: $4.78 info
Change: +$2.48 (+108%) info
Market Cap: $716.174M info
OABI
May 07, 2026, 4:25 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.47
Real-time Price: $4.78 info
Change: +$3.31 (+225%) info
Market Cap: $716.174M info